About Malaria – Aliquantumrx

Understanding Dormant Malaria

What makes P. vivax different

Malaria That Returns After the Initial Infection

Unlike other forms of malaria, Plasmodium vivax can persist silently in the liver as dormant forms called hypnozoites.
These dormant parasites may reactivate weeks or months later, causing relapse even after the bloodstream infection has been cleared.
This means a patient may appear cured — but still carry hidden liver-stage infection capable of restarting disease.

Why Relapse Matters

Relapse Drives Ongoing Disease Burden

Dormant liver-stage malaria is not a one-time illness. Repeated relapse can cause:

Recurring fever episodes and repeated illness
Severe anemia and increased health complications
Lost productivity and repeated healthcare burden
Continued malaria transmission within communities

Without eliminating dormant liver parasites, malaria returns.

Why Current Radical Cure Fails Millions

Current Treatments Require G6PD Testing Before Use

Today’s approved radical cure medicines (primaquine and tafenoquine) can trigger severe hemolysis in patients with G6PD deficiency. Because of this risk, blood testing is required before treatment. In many malaria-endemic regions:

G6PD testing is unavailable or inaccessible
Testing delays treatment decisions
Millions of patients never receive radical cure

80M+ Patients Cannot Access Radical Cure

As a result, a large proportion of patients remain untreated for dormant liver-stage malaria despite available medicines.

The Global Consequence

Untreated Relapse Sustains Transmission

When dormant malaria is left untreated:

Patients relapse repeatedly
Reinfection cycles continue
Transmission persists even where blood-stage malaria is controlled

Eliminating malaria requires stopping relapse at its source – in the liver.

Why a Test-Free Cure Matters

Removing the Testing Barrier Could Transform Access

Such an approach could:

Reach patients currently excluded from treatment
Simplify care delivery in low-resource regions
Support broader malaria eradication efforts

Our Approach

Advancing a New Path to Radical Cure

AliquantumRx is developing CALM (Cethromycin Against Liver-Stage Malaria), a program designed to eliminate dormant liver-stage malaria without the need for G6PD testing.

CALM is focused on creating a safer, scalable path toward relapse prevention and broader access to radical cure.